CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

This pharma stock was among the top gainers today!
Vishwesh Sanas
/ Categories: Trending, Mindshare

This pharma stock was among the top gainers today!

The stock surged 5.3 per cent and closed trading at Rs 407.65.

On December 9, the shares of Jubilant Pharmova Ltd surged 5.3 per cent and closed trading at Rs 407.65. The stock opened at Rs 383.95 and made an intraday high and low of Rs 423.55 and Rs 383.95, respectively.  

  

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company which operates under three business segments - pharmaceuticals, contract research, and development services & proprietary novel drugs. The company was recently in the news for signing a USD 150 million deal with the US army to boost vaccine manufacturing capacity in the US.  

 

The company expects to incur capex of around Rs 700-750 crore in FY23 primarily towards expansion in the CMO business and enhancement of drug discovery services capabilities and capacities.  

 

The company's poor quarterly performance continued. On a year-over-year basis, sales in Q2FY223 were down 3.5 per cent. Also, on a YoY basis, a significant decrease of 96.55 per cent was witnessed in net profit, dropping from Rs 142.64 crore in Q2FY22 to Rs 4.92 crore in Q2FY23. Due to poor demand in the API industry, price constraints, and regulatory uncertainties, the company's performance has been lacklustre in the last few quarters.   

 

About the shareholding pattern, 50.67 per cent of the company’s stake is owned by the promoters, 23.06 per cent by FIIs, 1.6 per cent by DIIs, and the rest 24.59 per cent by non-institutional investors.     

 

The company has a market capitalisation of Rs 6493 crore and the stock is trading at 78.87x PE. The scrip has a 52-week high and low at Rs 617 and Rs 305.2, respectively.  

Previous Article Stock below 100: This small-cap FMCG stock announces 8 crore buy-back. Do you own it?
Next Article Stock below Rs 50: Keep an eye on this multi-bagger IT stock which gave a return of more than 1000 per cent
Print
671 Rate this article:
3.6
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR